Ameren vs CMS Energy
AEE and CMS side by side, both in combination electric and gas, and other utility. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AEE and CMS compare
Ameren is the larger company, worth 1.4 times as much as CMS Energy ($30.6B against $22.0B).
On earnings, Ameren is cheaper: it trades at 19.5× trailing earnings, against 21.1× for CMS Energy.
CMS Energy grew revenue faster over the last twelve months (9.9% versus 3.8% for Ameren).
Both pay dividends: Ameren yields 2.7% and CMS Energy 3.2%.
CMS Energy scores higher on the StockData Score (9 against 4 for Ameren), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AEE | CMS |
|---|---|---|
| Size and price | ||
| Market cap | $30.6B | $22.0B |
| Share price | $110.54 | $70.10 |
| Change, 1 year | 8.1% | −3.0% |
| Change, 5 years | 29.3% | 15.8% |
| Beta (5Y) | 0.37 | 0.28 |
| Employees | – | 8,350 |
| StockData Score | ||
| Total score | 4 | 9 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 2 | 2 |
| Valuation | ||
| P/E | 19.5× (better) | 21.1× |
| P/S | 3.5× | 2.5× (better) |
| P/B | 2.2× (better) | 2.2× |
| EV/EBITDA | 13.7× (better) | 13.7× |
| PEG | 2.18 (better) | 2.85 |
| FCF yield | −4.6% | – |
| Fair value | $103.62 | $73.23 |
| Margin of safety | −6.7% | 4.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 3.8% | 9.9% (better) |
| Revenue growth, 5Y average | 8.7% (better) | 5.9% |
| Net income growth (TTM) | – | 0.29% |
| EPS growth (TTM) | 24.8% (better) | −1.8% |
| EPS growth, 5Y average | 8.9% (better) | 6.0% |
| Profitability | ||
| Operating margin | 24.9% (better) | 18.9% |
| Net margin | – | 11.6% |
| FCF margin | −16.0% | – |
| Return on equity | – | 11.3% |
| Return on invested capital | 5.9% (better) | 4.9% |
| Financial health | ||
| Debt / equity | 1.59 (better) | 1.95 |
| Net debt / EBITDA | 5.68 (better) | 6.22 |
| Interest coverage | 2.6× (better) | 2.0× |
| Current ratio | 0.53 | 0.94 (better) |
| Altman Z-score | 0.90 (better) | 0.86 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | 2.7% | 3.2% (better) |
| Years of dividend growth | 12 | 16 (better) |
| Dividend growth, 5Y average | 7.3% (better) | 5.9% |
| Buyback yield | −1.9% (better) | −4.7% |
| Shareholder yield | 0.81% (better) | −1.5% |
| Ownership | ||
| Held by institutions | 88.5% | 101% |
| Held by insiders | 0.36% | 0.58% |
| Insider net buying, 12 months | −$8.7M | −$1.9M (better) |
| Short interest, % of float | 5.2% | – |
Go deeper
- AEE stock overview
- AEE income statement
- AEE valuation and score
- CMS stock overview
- CMS income statement
- CMS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.